Valuation Update With 7 Day Price Move • May 12
Investor sentiment deteriorates as stock falls 34% After last week's 34% share price decline to €54.14, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 50% over the past year. 공시 • May 07
TransMedics Group, Inc. Reiterates Earnings Guidance for the Financial Year 2026 TransMedics Group, Inc. reiterated earnings guidance for the financial year 2026. For the year, the company expects revenue guidance to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company's prior year revenue. Reported Earnings • May 06
First quarter 2026 earnings released: EPS: US$0.21 (vs US$0.76 in 1Q 2025) First quarter 2026 results: EPS: US$0.21 (down from US$0.76 in 1Q 2025). Revenue: US$173.9m (up 21% from 1Q 2025). Net income: US$7.32m (down 72% from 1Q 2025). Profit margin: 4.2% (down from 18% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Medical Equipment industry in Italy. 공시 • May 02
Montreal Heart Institute and Chu Sainte-Justine Debut Transmedics Organ Care System Heart Montreal Heart Institute and CHU Sainte-Justine are set to begin using a cutting-edge device that will expand access to cardiac transplantation. The TransMedics Organ Care System (OCS) Heart, a device designed to preserve donor hearts and transport them under near-physiological conditions, is making its debut at the Montreal Heart Institute (MHI) and CHU Sainte-Justine. With standard methods, a heart can only be kept on ice for four to six hours. The OCS Heart is a perfusion system that safely keeps the heart beating and oxygenated for longer periods of time. As a result, it increases the number of donated organs that can be transported, thereby improving the odds of an adult or pediatric patient on the waiting list of receiving a transplant. Many patients are waiting for a life-saving transplant procedure at the MHI and CHU Sainte-Justine. In fact, a transplant candidate in Quebec will spend an average of 204 days on a waiting list – a period defined by constant uncertainty. Moreover, the number of people awaiting a transplant increased from 856 to 898 between 2024 and 2025. Of this number, 67 were waiting for a heart transplant in 2025. A heart transplant requires a close collaboration between myriad parties. Transplant Québec plays a pivotal role in coordinating organ donation, managing waiting lists, and overseeing organ recoveries across the province. The OCS Heart will be used to facilitate these processes. It will provide more flexibility for transporting and evaluating donor organs, in particular when recipients are located a long distance from the point of collection. 공시 • Apr 23
TransMedics Group, Inc. Provides Update On Ongoing Clinical Programs And Unveils Controlled Hypothermic Organ Preservation System TransMedics Group, Inc. provided an update on its ongoing clinical programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting in Toronto, Canada. At the meeting, TransMedics will unveil its new controlled, active cooling preservation device, the Controlled Hypothermic Organ Preservation System (CHOPS), aimed at facilitating the enrollment of the control arms of the OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials. CHOPS is a true active cooling device that provides a consistent and stable controlled cold storage environment for donor organs at a variety of temperature ranges that are established based on the recipient transplant program's preferences. In comparison, other current cold storage techniques use phase changing material that makes it difficult to control or adjust temperatures. CHOPS will be regulated by the U.S. Food and Drug Administration as a new, stand-alone device for controlled hypothermic preservation. TransMedics will submit an Investigation Device Exemption amendment to allow CHOPS to serve as the control arm for both Part B of ENHANCE Heart and DENOVO Lung Trials. The FDA granted full approval of TransMedics' Investigation Device Exemption for the Next-Generation OCS ENHANCE Heart trial in February 2026 and of the company's Investigation Device Exemption for its Next-Generation OCS DENOVO Lung trial in January 2026. Part B of the ENHANCE trial is designed to assess the superiority of OCS Heart perfusion in donation after brain death cases when compared to donation after brain death cases using static cold storage methods. The OCS DENOVO trial is designed to assess the superiority of OCS Lung perfusion in donation after brain death and donation after circulatory death cases when compared to cases using static cold storage methods. 공시 • Apr 22
TransMedics Group, Inc. to Report Q1, 2026 Results on May 05, 2026 TransMedics Group, Inc. announced that they will report Q1, 2026 results After-Market on May 05, 2026 공시 • Apr 13
TransMedics Group, Inc., Annual General Meeting, May 20, 2026 TransMedics Group, Inc., Annual General Meeting, May 20, 2026. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €84.18, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 16x in the Medical Equipment industry in Italy. Recent Insider Transactions • Mar 06
Key Executive recently sold €353k worth of stock On the 2nd of March, Nicholas Corcoran sold around 3k shares on-market at roughly €119 per share. This transaction amounted to 9.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Nicholas' only on-market trade for the last 12 months. Reported Earnings • Feb 25
Full year 2025 earnings released: EPS: US$5.60 (vs US$1.07 in FY 2024) Full year 2025 results: EPS: US$5.60 (up from US$1.07 in FY 2024). Revenue: US$605.5m (up 37% from FY 2024). Net income: US$190.3m (up 437% from FY 2024). Profit margin: 31% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Italy. 공시 • Feb 25
TransMedics Group, Inc. Provides Earnings Guidance for the Financial Year 2026 TransMedics Group, Inc. provided earnings guidance for the financial year 2026. For the year, the company expects total revenue to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company's prior year revenue. 공시 • Feb 11
TransMedics Group, Inc. to Report Q4, 2025 Results on Feb 24, 2026 TransMedics Group, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026 공시 • Feb 10
TransMedics Group, Inc. Receives Full and Unconditional FDA Ide Approval for Next-Generation OCS Heart Enhance Trial TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This follows full FDA approval of the company's Next-Generation OCS DENOVO Lung IDE trial in January 2026 and conditional IDE approval for the ENHANCE Heart trial in August 2025. The ENHANCE trial is a two-part clinical trial. Part A is designed to support prolonged heart perfusion using OCS™? Heart System. Part B is intended to demonstrate the superiority of OCS Heart perfusion in donation after brain death (DBD) cases when compared to DBD cases using static cold storage methods. Some of the key factors that could cause actual results to differ include: the fluctuation of financial results from quarter to quarter; ability to attract, train, and retain key personnel; existing and any future indebtedness, including the ability to scale its manufacturing and sterilization capabilities to meet increasing demand for the products; the rate and degree of market acceptance of the OCS; ability to educate patients, surgeons, transplant centers and private and public payors of benefits offered by the OCS; ability to maintain regulatory approvals or clearances for the OCS products in the United States, the European Union, and other select jurisdictions worldwide; ability to adequately respond to Food and Drug Administration ("FDA"), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation reforming the U.S. healthcare system, Organ Procurement and Transplantation Network ("OPTN"), or the FDA; the performance of third-party suppliers and manufacturers; use of third parties to transport donor organs and medical personnel for the NOP and the ability to maintain and grow logistics capabilities to support NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for aviation transportation services or other acquisitions, joint ventures or strategic investments; ability to maintain Federal Aviation Administration ("FAA") or other regulatory licenses or approvals for aircraft transportation services; price increases of the components of the products and maintenance, parts and fuel for aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against the information technology infrastructure; the economic, political and other risks associated with our foreign operations; ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid claims that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of any future U.S. government shutdowns; the extent and success of competing products or procedures that are or may become available; ability to service our 1.50% convertible senior notes, due 2028; the impact of any product calls or improper use of our products; the estimates regarding revenues; and our estimates regarding revenues; our existing and any future OCS™?; and our existing and any future future U.S. government government shutdowns; the ability to maintain the OCS Heart perfusion in donations after brain death (DBD). Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €121, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 15x in the Medical Equipment industry in Italy. Simply Wall St's valuation model estimates the intrinsic value at €216 per share. Recent Insider Transactions • Nov 19
Founder recently bought €863k worth of stock On the 17th of November, Waleed Hassanein bought around 9k shares on-market at roughly €98.29 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Waleed has been a buyer over the last 12 months, purchasing a net total of €2.6m worth in shares. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: US$0.71 (vs US$0.13 in 3Q 2024) Third quarter 2025 results: EPS: US$0.71 (up from US$0.13 in 3Q 2024). Revenue: US$143.8m (up 32% from 3Q 2024). Net income: US$24.3m (up 477% from 3Q 2024). Profit margin: 17% (up from 3.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Italy. 공시 • Oct 30
TransMedics Group, Inc. Raises Revenue Guidance of Its Full Year 2025 TransMedics Group, Inc. raised revenue guidance of its full year 2025. For the period, the company raising the midpoint and narrowing the range of its full year 2025 revenue guidance to $595 million to $605 million, which represents 36% growth at the midpoint compared to the company's prior year revenue. TransMedics' full year 2025 revenue guidance as reported on July 30, 2025 was previously in the range of $585 million to $605 million. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €115, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Medical Equipment industry in Italy. Simply Wall St's valuation model estimates the intrinsic value at €216 per share. Board Change • Oct 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • Oct 16
TransMedics Group, Inc. to Report Q3, 2025 Results on Oct 29, 2025 TransMedics Group, Inc. announced that they will report Q3, 2025 results After-Market on Oct 29, 2025 Board Change • Sep 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Recent Insider Transactions • Aug 10
Founder recently bought €1.7m worth of stock On the 7th of August, Waleed Hassanein bought around 17k shares on-market at roughly €101 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Waleed's only on-market trade for the last 12 months. 공시 • Aug 05
TransMedics Group, Inc. Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial. The ENHANCE trial is a two-part clinical trial. Part A is designed to support prolonged heart perfusion using OCS™? Heart System. Part B is intended to demonstrate the superiority of OCS Heart perfusion in donation after brain death (DBD) cases when compared to DBD cases using static cold storage methods. Part B is intended to support the potential expansion of OCS Heart clinical indications to include DBD hearts that are not currently eligible for OCS perfusion and preservation. The trial's total sample size, across both Part A and Part B, is expected to exceed 650 patients. TransMedics believes this would constitute the largest heart preservation for transplant trial ever, worldwide. Reported Earnings • Jul 31
Second quarter 2025 earnings released: EPS: US$1.03 (vs US$0.37 in 2Q 2024) Second quarter 2025 results: EPS: US$1.03 (up from US$0.37 in 2Q 2024). Revenue: US$157.4m (up 38% from 2Q 2024). Net income: US$34.9m (up 186% from 2Q 2024). Profit margin: 22% (up from 11% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy. 공시 • Jul 31
TransMedics Group, Inc. Revises Revenue Guidance for the Full Year 2025 TransMedics Group, Inc. revised revenue guidance for the full year 2025. The company is raising its full year 2025 revenue guidance to be in the range of $585 million to $605 million, which represents 35% growth at the midpoint compared to the company's prior year revenue. The company’s full year 2025 revenue guidance as reported on May 8, 2025, was previously in the range of $565 million to $585 million. Board Change • Jul 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • Jul 17
TransMedics Group, Inc. to Report Q2, 2025 Results on Jul 30, 2025 TransMedics Group, Inc. announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • May 09
Transmedics Group, Inc. Revises Revenue Guidance for the Full Year 2025 TransMedics Group, Inc. revised revenue guidance for the full year 2025. For the year, the company expects revenue guidance to be in the range of $565 million to $585 million, which represents 30% growth at the midpoint compared to the company's prior year revenue. TransMedics' full year 2025 revenue guidance as reported on February 27, 2025 was previously in the range of $530 million to $552 million. 
